Last modified by Sarantis Dimitriadis on 2023/12/08 13:20
From version 5.8
edited by Sarantis Dimitriadis
on 2022/06/07 08:45
Change comment: There is no comment for this version
To version 6.1
edited by Sarantis Dimitriadis
on 2023/05/30 09:33
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -7,6 +7,8 @@
7 7  (% class="western" lang="en-GB" style="text-align:justify" %)
8 8  (% lang="en-US" %)End users can be classified to non-professional and professional groups. Typical non-professional and professional end-user groups in health and wellbeing includes the following:
9 9  
10 +:
11 +
10 10  * (((
11 11  (% lang="en-US" %)**Non-professional end users:**
12 12  
... ... @@ -15,6 +15,8 @@
15 15  * (% lang="en-US" %)**Public health and social service clients: **Those who use public services.
16 16  )))
17 17  
20 +:
21 +
18 18  * (((
19 19  (% lang="en-US" %)**Professional end users**
20 20  
... ... @@ -25,9 +25,13 @@
25 25  * (% lang="en-US" %)**Policy and decisions makers:** Those responsible for making policies and decisions at local, regional, national or international level.
26 26  )))
27 27  
32 +:
33 +
28 28  (% class="western" lang="en-GB" %)
29 29  (% lang="en-US" %)**Business-to-Business Customer (B2B):** B2B-customer is an organization that purchases living lab services from a living lab. B2B-customers can be classified to private, public, education/ research, civil society organizations and networks/cluster groups as follows:
30 30  
37 +:
38 +
31 31  * (((
32 32  (% lang="en-US" %)**Private sector organizations: **(business developers and researchers)
33 33  
... ... @@ -42,6 +42,8 @@
42 42  * (% lang="en-US" %)Pharmaceutical companies
43 43  )))
44 44  
53 +:
54 +
45 45  * (((
46 46  (% lang="en-GB" %)
47 47  (% lang="en-US" %)**Public sector organizations:**
... ... @@ -57,6 +57,8 @@
57 57  * (% lang="en-US" %)**Public funder:** Government or other European, national, regional or local public institutions who is providing public funding for a specific living lab living lab research project via call for application process.
58 58  )))
59 59  
70 +:
71 +
60 60  * (((
61 61  (% lang="en-GB" %)
62 62  (% lang="en-US" %)**Education and research organizations:**
... ... @@ -70,6 +70,8 @@
70 70  * (% lang="en-US" %)**Private research organizations** such as technology and innovation centers
71 71  )))
72 72  
85 +:
86 +
73 73  * (((
74 74  (% lang="en-GB" %)
75 75  (% lang="en-US" %)**Civil society organizations:**
... ... @@ -77,6 +77,8 @@
77 77  * (% lang="en-US" %)Non-governmental organizations (NGO) and nonprofit entities operating at international, national, regional or local level.
78 78  )))
79 79  
94 +:
95 +
80 80  * (((
81 81  (% lang="en-GB" %)
82 82  (% lang="en-US" %)**Networks and clusters:**
... ... @@ -85,14 +85,13 @@
85 85  * (% lang="en-US" %)International, national, regional and local networks
86 86  )))
87 87  
104 +:
105 +
88 88  (% class="western" lang="en-GB" %)
89 -(% lang="en-US" %)Typical approaches to define (%%)non-professional end users (a.k.a. study participants) in health and wellbeing living lab projects are presented in Table .
107 +(% lang="en-US" %)Typical approaches to define (%%)non-professional end users (a.k.a. study participants) in health and wellbeing living lab projects are presented in the following table .
90 90  
91 -(% style="margin-left:auto; margin-right:auto" %)
92 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:11px; text-align:center; vertical-align:middle; width:634px" %)(((
93 -(% class="western" lang="en-GB" style="text-align:center" %)
94 -(% lang="en-US" %)**Age or age group**
95 -)))
109 +(% style="height:1004px; margin-left:auto; margin-right:auto; width:1694px" %)
110 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:11px; text-align:center; vertical-align:middle; width:634px" %)**Age groups**
96 96  |(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
97 97  (% lang="en-US" %)Specific age range
98 98  )))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
... ... @@ -104,145 +104,47 @@
104 104  (% class="western" %)
105 105  
106 106  )))
107 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
108 -(% class="western" lang="en-GB" %)
109 -(% lang="en-US" %)Elderly
110 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)(((
111 -(% class="western" lang="en-GB" %)
112 -(% lang="en-US" %)Adults
113 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)(((
114 -(% class="western" lang="en-GB" %)
115 -(% lang="en-US" %)Youth
116 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)(((
117 -(% class="western" lang="en-GB" %)
118 -(% lang="en-US" %)Children
119 -)))
122 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)Adolescents|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)Adults|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)Older Adults|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)General Population
120 120  |(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)(((
121 121  (% class="western" %)
122 122  
123 123  )))
124 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)(((
125 -(% class="western" lang="en-GB" style="text-align:center" %)
126 -(% lang="en-US" %)**Health status**
127 -)))
127 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**Adolescents Health status (disease, disorder or disability)**
128 128  |(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
129 129  (% class="western" lang="en-GB" %)
130 130  (% lang="en-US" %)Healthy
131 131  )))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)(((
132 132  (% class="western" lang="en-GB" %)
133 -(% lang="en-US" %)Patient
133 +
134 134  )))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)(((
135 135  (% class="western" lang="en-GB" %)
136 -(% lang="en-US" %)Rehabilitant
136 +
137 137  )))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)(((
138 138  (% class="western" lang="en-GB" %)
139 -(% lang="en-US" %)Recovered/Survivor
139 +
140 140  )))
141 141  |(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)(((
142 142  (% class="western" %)
143 143  
144 144  )))
145 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)(((
146 -(% class="western" lang="en-GB" style="text-align:center" %)
147 -(% lang="en-US" %)**A specific disease, disorder or disability**
148 -)))
149 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
150 -(% class="western" lang="en-GB" %)
151 -(% lang="en-US" %)ADHD
152 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
153 -(% class="western" lang="en-GB" %)
154 -(% lang="en-US" %)Dementia
155 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
156 -(% class="western" lang="en-GB" %)
157 -(% lang="en-US" %)Parkinsons’ disease
158 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
159 -(% class="western" lang="en-GB" %)
160 -(% lang="en-US" %)Loneliness and Social Isolation
161 -)))
162 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
163 -(% class="western" lang="en-GB" %)
164 -(% lang="en-US" %)Autism
165 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
166 -(% class="western" lang="en-GB" %)
167 -(% lang="en-US" %)Down syndrome
168 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
169 -(% class="western" lang="en-GB" %)
170 -(% lang="en-US" %)Physical disability
171 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
172 -(% class="western" lang="en-GB" %)
173 -(% lang="en-US" %)Mental health
174 -)))
175 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
176 -(% class="western" lang="en-GB" %)
177 -(% lang="en-US" %)Cardiovascular disease
178 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
179 -(% class="western" lang="en-GB" %)
180 -(% lang="en-US" %)Idiopathic pulmonary fibrosis (IPF)
181 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
182 -(% class="western" lang="en-GB" %)
183 -(% lang="en-US" %)Sleep apnea/apnea
184 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
185 -(% class="western" lang="en-GB" %)
186 -(% lang="en-US" %)Mild cognitive impairment
187 -)))
188 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
189 -(% class="western" lang="en-GB" %)
190 -(% lang="en-US" %)Chronic Obstructive Pulmonary Disease (COPD)
191 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
192 -(% class="western" lang="en-GB" %)
193 -(% lang="en-US" %)Language disability
194 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
195 -(% class="western" lang="en-GB" %)
196 -(% lang="en-US" %)Substance abuse (drugs, alcohol)
197 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
198 -(% class="western" lang="en-GB" %)
199 -(% lang="en-US" %)Multiple sclerosis
200 -)))
201 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
202 -(% class="western" lang="en-GB" %)
203 -(% lang="en-US" %)Cognitive disorder (mild, major)
204 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
205 -(% class="western" lang="en-GB" %)
206 -(% lang="en-US" %)Intellectual disability/ Learning difficulty/ Mental retardation
207 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
208 -(% class="western" lang="en-GB" %)
209 -(% lang="en-US" %)Trauma patient
210 -
211 -(% class="western" lang="en-GB" %)
212 -(% lang="en-US" %)(e.g., a spinal cord injury)
213 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
214 -(% class="western" lang="en-GB" %)
215 -(% lang="en-US" %)Neurodegenerative diseases
216 -)))
145 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**Adults Health status (disease, disorder or disability)**
146 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)Healthy|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)Schizophrenia|Multiple-Sclerosis|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)Parkinson Disease
147 +|Post-Stroke Patients with Moving or Linguistic Disability|Mild Cognitive Impairment|Sleep Disorders: e.g., Apnea, Hypopnea|With Disability
148 +|Healthy with Possible Chronic Conditions|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %) |(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %) |(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)
217 217  |(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)(((
218 218  (% class="western" %)
219 219  
220 220  )))
221 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)(((
222 -(% class="western" lang="en-GB" style="text-align:center" %)
223 -(% lang="en-US" %)**Clients of a specific service**
224 -)))
225 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
226 -(% class="western" lang="en-GB" %)
227 -(% lang="en-US" %)Child welfare
228 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
229 -(% class="western" lang="en-GB" %)
230 -(% lang="en-US" %)Nursing home
231 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
232 -(% class="western" lang="en-GB" %)
233 -(% lang="en-US" %)Employment service
234 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
153 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**Older Adults Health status (disease, disorder or disability)**
154 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)Healthy|Parkinson Disease|Mild Cognitive Impairment|With Disability|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
235 235  (% class="western" %)
236 236  
237 237  )))
238 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
158 +|Healthy with Possible Chronic Conditions|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
239 239  (% class="western" lang="en-GB" %)
240 -(% lang="en-US" %)Early childhood education
160 +
241 241  )))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
242 242  (% class="western" lang="en-GB" %)
243 -(% lang="en-US" %)Home care
244 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
245 -(% class="western" lang="en-GB" %)
246 246  
247 247  )))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
248 248  (% class="western" lang="en-GB" %)
... ... @@ -252,68 +252,20 @@
252 252  (% class="western" %)
253 253  
254 254  )))
255 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)(((
256 -(% class="western" lang="en-GB" style="text-align:center" %)
257 -(% lang="en-US" %)**Vulnerable groups**
258 -)))
259 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
172 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**General Population Health status (disease, disorder or disability)**
173 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)Healthy|Ipf Patients|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)Prostate Cancer|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
260 260  (% class="western" lang="en-GB" %)
261 -(% lang="en-US" %)Minors/Children
262 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
263 -(% class="western" lang="en-GB" %)
264 -(% lang="en-US" %)Single parents with minor children
265 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
266 -(% class="western" lang="en-GB" %)
267 -(% lang="en-US" %)Persons subjected to psychological, physical or sexual violence
268 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
269 -(% class="western" lang="en-GB" %)
270 -(% lang="en-US" %)Substance users
271 -
272 -(% class="western" lang="en-GB" %)
273 -(% lang="en-US" %)(drugs, alcohol)
175 +Down Syndrome
274 274  )))
275 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
177 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)Chronical Diseases: e.g., Persons With Chronic Pulmonary (Copd)|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)Cardiological Or Other Conditions (Aphasia)|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)Breast Cancer Survivors|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
276 276  (% class="western" lang="en-GB" %)
277 -(% lang="en-US" %)Disabled people
278 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
279 -(% class="western" lang="en-GB" %)
280 -(% lang="en-US" %)Victims of trafficking in human beings
281 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
282 -(% class="western" lang="en-GB" %)
283 -(% lang="en-US" %)Ethnic minorities and immigrants
284 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
285 -(% class="western" lang="en-GB" %)
286 -(% lang="en-US" %)Isolated people
287 -)))
288 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
289 -(% class="western" lang="en-GB" %)
290 -(% lang="en-US" %)Elderly people
291 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
292 -(% class="western" lang="en-GB" %)
293 -(% lang="en-US" %)Persons with serious illnesses
294 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
295 -(% class="western" lang="en-GB" %)
296 -(% lang="en-US" %)Homeless people
297 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
298 -(% class="western" lang="en-GB" %)
299 -(% lang="en-US" %)Ex-prisoners and people with criminal background
300 -)))
301 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:12px; text-align:left; vertical-align:middle; width:153px" %)(((
302 -(% class="western" lang="en-GB" %)
303 -(% lang="en-US" %)Pregnant women
304 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
305 -(% class="western" lang="en-GB" %)
306 -(% lang="en-US" %)Persons with mental disorders
307 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
308 -(% class="western" lang="en-GB" %)
309 309  
310 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
311 -(% class="western" lang="en-GB" %)
312 -
313 313  )))
314 314  
182 +:
183 +
315 315  (% class="western" lang="en-GB" %)
316 -(% lang="en-US" style="page-break-before:always" %)Living lab research infrastructure end users and B2B-customers (% style="page-break-before:always" %)in health and wellbeing living lab projects are presented in Table .
185 +(% lang="en-US" style="page-break-before:always" %)Living lab research infrastructure end users and B2B-customers (% style="page-break-before:always" %)in health and wellbeing living lab projects are presented in (%%)the table below(% style="page-break-before:always" %) .
317 317  
318 318  |**Researcher expertise**|**Brief use case description**
319 319  |Policy Makers|Studying the impact of new service models or new collaboration models in healthcare, designing or improving policies, gathering requirements for improving health and wellbeing of citizens, co-creation of research methodologies for policy making

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101007990

Copyright © 2021 VITALISE Project